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Abstract 
Background: Melanoma incidence is increasing in the US, with 62,190 
Americans projected to be diagnosed with some form ofthe skin cancer in 2006. 
Despite its increasing incidence and the assumption that early intervention can 
lead to a cure, no preventive method is supported by defmitive evidence, and 
mortality rates remain relatively stable. Most funding has been devoted to 
education campaigns advocating sun avoidance and sunscreen use (primary 
prevention) and regular skin examinations (secondary prevention), especially 
among populations considered to be at highest risk. Recently campaigns 
encouraging patient awareness and early detection have gained attention as a 
tertiary prevention method. 
Objective: This research project will review current methods used in melanoma 
prevention and propose an education-oriented approach to decreasing morbidity 
and mortality from melanoma. 
Methods: The most recent melanoma literature will be reviewed systematically, 
with an emphasis on prevention methods currently being employed. A 
manuscript will be drafted of our proposed research project, a 40-question survey 
evaluating pre-disease awareness in newly diagnosed melanoma patients. 
Conclusion: There is insufficient evidence to support or disprove any particular 
melanoma prevention modality currently being used. Based on available 
information, we believe greater improvement in melanoma statistics will be 
realized if prevention methods are broader and include greater emphasis on public 
education campaigns so that patients are aware of what skin lesions warrant 
medical evaluation. Still, we concede that more research is needed. First, future 
studies should ascertain the genetic and environmental etiology of melanoma. 
Next, epidemiologic investigations should better establish which populations have 
the highest rates of mortality, focusing on the histological classification of high-
risk lesions in addition to the demographic characteristics of high-risk patients. 
Lastly, current prevention plans should be evaluated on a large-population scale 
with future works addressing the associated costs and estimated effects on both 
the morbidity and mortality of melanoma. 
What You Know May Save You: Pre-Disease Awareness and Delay in 
Seeking Evaluation for Malignant Melanoma 
Crystal Brooks MPH, Nancy Thomas MD, PhD. and Karyn Stitzenburg MD. MPH 
Context: Melanoma incidence is increasing in the United States, with 62,190 
Americans projected to be diagnosed with some form of the skin cancer in 2006. 
Despite its increasing incidence and the assumption that early intervention can 
lead to cure, no preventive method has been proven effective definitively, and 
mortality rates remain relatively stable. 
Objective: The project objective is to develop a research protocol evaluating the 
relationship between a patient's pre-disease awareness and his delay in seeking 
medical evaluation of a suspicious skin lesion. 
Proposed Design and Setting: We developed a 40-question survey to be 
administered to newly diagnosed melanoma patients seeking treatment at the 
University of North Carolina healthcare system clinics over a one-year period. 
Main Outcome Measure: The association between (pre-diagnosis) melanoma 
awareness and time elapsed in seeking medical evaluation of a suspicious skin 
lesion using simple correlation coefficients (Student's t-test). 
Results: To be determined 
Conclusion: We propose that those melanoma patients with greater disease 
awareness prior to their diagnosis will have a shorter elapsed time between their 
recognizing a suspicious skin lesion and seeking medical evaluation of that 
lesion. We believe these data will lend greater support to public health efforts 
that emphasize the importance of patient awareness and their seeking prompt 
medical attention when suspicious lesions arise. 
INTRODUCTION 
While skin cancer screening is encouraged by dermatologic organizations, 
current research does not indicate screening has improved mortality rates. 1• 2 
Though improvements in 5-year survival have been reported, the increase in the 
number of biopsies performed appear to have produced an artifact of exaggerated 
malignant melanoma incidence, suggesting over-diagnosis of thin, non-malignant 
tumors in screened populations.1·3 Many believe these data reveal the inadequacy 
of skin cancer screening protocols while others focus on the benefit of identifying 
any melanoma early. This scientific debate demonstrates the need for greater 
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evaluation of skin cancer screening as well as more research of other early 
detection models that may he more effective than those currently employed. 
2 
The visual manifestation of most melanoma tumors make them unique in the 
ability to be detected at an early stage.4 Still, among patients with invasive 
disease, there is a significant lag between symptom I sign presentation and 
seeking medical evaluation. 4"6 Reduction in diagnostic delay has been adopted as 
a national strategy by the British government to improve cancer morbidity and 
mortality rates, 6 a country with a slightly lower melanoma incidence than that 
found in the United States. 7• 8 Various organizational strategies have been 
employed to minimize delay between the first evaluation of symptoms and 
diagnosis.6 However, addressing only organizational factors related to delay 
overlooks associated patient contributions. Cancer research literature 
demonstrates that one of the primary factors associated with diagnostic delay is 
the patient's failure to recognize symptoms as problems related to malignancy.6 
One promising preventive approach, therefore, is to increase patient awareness of 
dermatologic changes in order to decrease delays in seeking medical attention. 
The diagnostic course of melanoma involves (1) lesion appearance, (2) 
recognition of abnormality I development of concern regarding the lesion, (3) 
seeking medical attention and ( 4) diagnosis. Secondary prevention through 
clinical screening and regular skin self examinations has not been supported 
because of the costs, both temporal and financial, to the healthcare system. As 
early detection may provide a strong opportunity for mortality reduction, global 
education campaigns for the general public and physicians alike are being 
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recommended to increase awareness and recognition of cutaneous melanoma.9. 11 
Because patients have a principal role not just in detecting their cancer but 
seeking treatment as well, it is important to identifY those factors that affect 
patients' health behavior. In our study, we will survey patients undergoing 
treatment for cutaneous melanoma in a university-hospital subspecialty clinic to 
assess the relationship between the patient's prior awareness of melanoma and 
his/her likelihood of seeking medical attention for the skin lesion of concern. 
METHODS 
Sample 
Our sample will be comprised of 80 patients of various ages undergoing 
treatment for cutaneous invasive melanoma at a university hospital-based clinic. 
Patients will be notified of the study by their treating physician and asked about 
their willingness to participate by clinic staff during a telephoned appointment 
reminder. Exclusion criteria are prior diagnosis of melanoma and diagnosis of 
melanoma more than 3 months prior to study enrollment. We further limited our 
study sample by excluding those patients with in-situ lesions. Questionnaires 
were self-administered and written in English. No translation ofthe text was 
available. The research protocol was reviewed and approved by the Institutional 
Review Board of the University of North Carolina. 
Development and administration of survey instrument 
A 40-item survey instrument was developed to determine delay and pre-
diagnostic awareness based on questions used in previously published studies 
3 
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assessing melanoma awareness and knowledgeOS' 12 This questionnaire will be 
piloted on 15 participants, Those questions that are frequently misinterpreted by 
subjects will be modified or eliminated, Participants in the pilot will be excluded 
from final analysis, 
We defined patient-associated medical delay as the time between the 
respondent becoming concerned about his or her lesion and the first physician's 
evaluation of that mark. Using power analysis, we previously determined the 
sample size needed to detect a 3 month difference of delay between those with 
high or low-disease awareness and the expected delay of approximately 169 days 
in general melanoma populations, Time period estimates were based on those 
used in previously published reports, !3, 14 The minimal sample size needed was 
calculated at 38 patients, but to account for any drop-outs (i,e, refusal to complete 
survey, incomplete surveys), we will use a sample size of 80 patients to ensure 
our minimum is met 
The survey asks respondents about various aspects of their melanoma 
healthcare experience, including (1) patient's prior awareness of disease 
(knowledge of disease definitions and characteristics, their awareness of risk 
factors, social familiarity with disease), (2) patient's skin awareness before 
diagnosis (including use of self-examination of skin), (3) patient's usual 
healthcare pattern, and ( 4) details of the medical evaluation for the suspicious skin 
mark. Pre-melanoma awareness is rated on a scale of 0- 30 with 0 indicating no 
prior disease awareness and 30 indicating strong awareness of melanoma prior to 
diagnosis, To ensure the association between pre-disease awareness and health 
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seeking behavior is not confounded by unfamiliarity with the healthcare system, 
we included an assessment of health literacy, using three questions adapted from 
the Short Test of Functional Health Literacy in Adults (S-TOHFLA) that address 
difficulty learning of medical disorders, confidence with medical forms, and 
requirement for assistance when reading health-related materials. 15 Following 
completion of the questionnaire, research staff will access medical records to 
obtain Breslow depth and Clark length. 
Variables 
The primary outcome of interest is the reported time period between the date 
when the patient became concerned about his I her skin mark and the date of 
visiting a physician for evaluation of the lesion. The principal independent 
variable is the patient's pre-melanoma awareness. Breslow depth is an additional 
outcome variable with analysis of its correlation to both medical delay as well as 
pre-disease awareness. 
Statistical analysis 
After dichotomizing awareness scores (low awareness: score < X; high-
awareness: score >= X), we compared medical delay in low vs. high-awareness 
patients using the Student's t-test. We also performed multivariate analysis of 
individual patient awareness components to determine their associations with 
medical delay and Breslow depth. Clark length is included only if needed at a 
later date for comparison to previously published data. We adjusted for other 
factors (usual pattern ofhealthcare, including usual dermatologic care, skin 
awareness, and assistance in detection) to indicate whether or not our association 
5 
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was modified by any of these covariates. STAT A software version 9.0 will be 
used for statistical analysis. 16 
RESULTS 
In Table 1, characteristics of our sample will be presented as proportions of the 
total number of 
study Table 1: Characteristics of Melanoma Study Population (n = 80) 
Characte~'i. Value 
respondents. Sex(%) 
Malo All results with percent values will be expressed in "n (%)". 
Female 
First, we will Race(%) White 
Black 
determine if Hispanic I Latino Asian I Pacific Islander 
Oth" 
Mean ae:e (yrs 
there is a Median Breslow tumor thickness (mm 
Married(%) 
y, 
correlate between No Income(%) 
Less than $25,000 
$25,000 ~ $49,999 
awareness score $50,000- $74,999 
More than $75,000 
Health Insurance(%) 
and patient- y" No 
Home Community(%) 
associated Rural/Farm Rural/ Non-Fann 
Small Town 
medical delay. 
City 
Urban Area 
Metrouolitan Area 
Mean Health Literacy Score 
Additionally, we %Adequate Literacy % Marginal Literacy 
% Inad~uate Litenicv 
will evaluate the High school graduate(%) y" 
No 
range of 
Social familiarity with Melanoma(%) 
y, 
No 
awareness scores and determine if scores vary based on demographic information 
(including distance from evaluating physician), with data presented in Table 2. 
To finish, we will establish the distribution of pre-disease awareness in our study 
population (i.e. is the number of highly aware greater than, less than, or equal to 
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those who are less aware) and compare our rates to those published in past 
research studies. 
Table 2: Analysis of association between low versus high disease awareness and potential 
predictors: of prtHiiagnosis disease awareness 
Characteristics Low Disease !Jig! P-value* 
Awareness Disease 
n-x Awareness 
n "Y 
Median Breslow tumor thickness (mm) 
Sex(%) 
Mrue 
Female 
Mean a e (yrs) 
High School Graduate(%) 
y, 
No 
Income("/ .. ) 
Less than $25,000 
$25,000-$49,999 
$50,000 - $74,999 
More than $75,000 
Married (%•) 
y, 
No 
Mean Health Literacy &ore 
% Adequate Literacy 
% Marginal Literacy 
%Inadequate Literacy 
Social familiarity with Melanoma(%) 
y, 
No 
Health Insurance(%) 
y, 
No 
*p value for student's t-test comparing means of the two disease awareness groups 
DISCUSSION 
A study evaluating melanoma awareness and skin self examinations 
conducted in the mid 1990s found the American public was poorly informed 
about the specific characteristics of melanoma, although globally aware of skin 
cancer.5 This lack of knowledge would promote complacency regarding 
dermatologic changes and create a false sense of security as patients negate the 
severity of their illness. In addition, if oblivious to the potential for cure at earlier 
stages of disease (as has been proposed throughout melanoma literature), patients 
7 
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are missing a crucial opportunity to avoid morbidity and mortality because of this 
lack of awareness. 
In this investigation, we chose to focus on pre-disease awareness and patients' 
seeking medical attention because subsequent stages of melanoma care are 
dependent on these factors. We believe our study will demonstrate that those 
patients who have greater awareness of melanoma have a shorter period of patient 
associated medical delay. Literature on melanoma awareness and health-seeking 
behavior is limited, but previous studies have drawn similar conclusions to our 
premise.12 We expanded on published data by investigating other features that 
may correlate to both disease awareness and delay in seeking medical attention. 
Our study included an assessment of health literacy while also addressing other 
potential confounders such as usual healthcare utilization patterns and social 
familiarity with melanoma. In addition, we limited our study sample to those 
patients with invasive melanoma, excluding those with in situ disease, to 
determine whether pre-disease awareness would have an effect on those cancer 
types more closely associated with mortality. 
Melanoma research is hampered by the qualitative nature of analysis required 
to establish potential risk factors and health seeking behavior prior to diagnosis. 
Retrospective surveys completed by patients are prone to "social desirability 
biases", recall bias and respondents' memory deficiencies. 17 Prospective analyses 
may eliminate some of the error introduced by memory deficits and minimize 
social desirability biases by evaluating behavior before the diagnosis is made. 
However, prospective studies would be difficult to implement especially in 
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countries with a relatively low melanoma incidence because the population 
followed (even if chosen from a larger population of those at greatest risk) would 
yield a small sample of malignant melanoma cases and require a very long 
follow-up. In addition, it may be hard to qualify or quantify changes in lesion 
characteristics, precluding our ability to assess the point when preventive 
intervention is most efficacious. Lastly, prospective studies would require 
respondents to document health behaviors (i.e. performance of self or clinical skin 
examinations, disease knowledge or exposure) which may maintain biases 
introduced by survey utilization. Overall, the requirements of prospective studies 
may prove cost-prohibitive to implementation. 
We used a number of different measures to counter problems encountered in 
previous investigations. We adapted our study instrument from previously 
published works to increase validity of the questions used. We attempted to 
control for recall bias by limiting study participation to those diagnosed with 
melanoma within 3 months of study entry. However, we acknowledge that a 
known melanoma diagnosis still may influence how participants thought about 
and reported their disease awareness and reasons for seeking medical care. 
Additionally, our small sample size as well as population homogeneity (primarily 
white North Carolinians) affect generalizability and may bias our association 
because of unaccounted shared confounding factors. Lastly, our study was 
focused on one particular aspect of the healthcare experience; therefore, broad 
generalizations about the conclusive association between patient awareness and 
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medical delay would be unwarranted, especially because of the cross-sectional 
study design. 
10 
Still, we believe the probable similarity of our results to previously reported 
data is important in determining a patient-related component to the diagnostic 
framework of melanoma. The next step is to better define the association between 
medical delay and diagnostic features of melanoma such as Breslow depth. If 
decreased delay is associated with diminished Breslow depth, there will be 
stronger support for the implementation of educational campaigns to increase 
public awareness of melanoma so that people know which features are suggestive 
of malignancy and know to act quickly when suspicious lesions arise. Both of 
which may decrease patient-related medical delay and ultimately postponement of 
diagnosis. 
We recognize that the jump from patient associated factors to diagnosis 
misses a number of key factors that may affect the overall outcome. Even if it is 
found that patient's lack of awareness increases delay in initially seeking medical 
evaluation, this does not wholly explain delay in diagnosis or the more distal 
outcome of Breslow depth. Blum et al found that "substantial" disease awareness 
did not preclude diagnostic delay and melanoma treatment, 10 supporting our idea 
of a multi-factorial etiology of delay. Investigating all of these potential 
correlates extend beyond the scope of what can be done in a succinct 
questionnaire. Optimally, our study will be one in a series of research 
investigating various fundamental factors that may lead to delay in diagnosis of 
melanoma. Used collectively, these studies should describe more adequately the 
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melanoma diagnostic process and demonstrate points of intervention that will 
decrease delay in diagnosis. 
C. Brooks eta/. I Health Care and Prevention Program~ Manuscript 
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lntroduction 
An Overview 
Addendum 1 
In 1996, melanoma incidence rates were reported to be 1800% of what they 
were in the 1930s.1 Authors suggested this increase in incidence was not an 
artifact of increased surveillance or better cancer-counting methods but an 
important increase in disease prevalence secondary to changes in environmental 
and social conditions.1 Ten years later, melanoma is cited as the fifth most 
common malignancy in the United States, with an incidence increasing at a rate 
faster than that of any other cancer. 2 Between 2005 and 2006, the number of new 
cases is expected to increase from an estimated 59,580 to 62,190, though 
mortality is projected to remain stable with an approximated increase of only 200 
deaths attributable to melanoma. 2• 3 However, because much of the data are based 
on the prevalence of thin or in-situ melanoma, which may never progress to 
malignant disease, the significance of some of these statistics becomes less 
certain. 
Melanoma Classification 
Melanomas are categorized into four subtypes based on clinical and 
pathologic determinants. The most common subtype is superficial spreading 
melanoma (SSM), which accounts for 70% of all diagnosed melanomas.4 
Superficial spreading melanomas are characterized by a period oflateral (radial) 
growth that predates more invasive, vertical growth by anywhere from 1 - 5 
years. 4 The vertical growth phase marks the period of greatest malignant 
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potential for superficial spreading melanomas since the tumor is most likely to 
metastasize to dermal lymphatics and blood vessels during this stage. 4 
The second most common melanoma is the nodular subtype, comprising 15 -
30% of diagnosed cases.4 Clinically, these lesions usually present as discrete, 
darkly pigmented nodules; they account for a large proportion of amelanotic 
melanomas.4 Nodular melanoma typically demonstrates vertical growth only, 
making identification of these lesions more difficult4 and the risk of morbidity and 
mortality greater. 
The lesser known subtypes of melanoma, each representing approximately 5% 
of the total, are acrallentiginous melanoma and lentigo maligna melanoma. 4 
Despite the lower incidence of acrallentiginous melanoma, it is the most common 
subtype among dark-skinned individuals and presents in inconspicuous areas such 
as the palms, soles, and nail beds. 4 Lentigo maligna melanoma, on the other 
hand, usually develops from in-situ melanoma on sun-damaged areas of the head 
and neck.4 
Diagnosis and Staging 
Although the presence of melanoma may be suggested by visual inspection by 
a trained healthcare professional, confirmation is required by biopsy and 
histological assessment. Excisional biopsy with non-diseased skin margins is the 
standard, both diagnostically and therapeutically.4 lncisional biopsies are only 
employed when a complete excision is impractical or melanoma suspicion is low.4 
Addendum 3 
Shave biopsies are contraindicated because they do not provide enough tissue for 
diagnosis and prohibit accurate depth measurement.4 
In 2002, the American Joint Committee on Cancer revised its staging system 
for cutaneous melanoma from the 1997 version, making the following changes: 
T-stage was to be defined by tumor thickness (mm), the distance from 
epidermal granular layer to tumor base at its thickest points (Breslow 
Depth), as well as the presence of ulceration. In addition, cut-off points 
for each stage were modified. 
Micro- and macrosatellites, in-transit, and nodal metastases were used to 
represent lymphatic dissemination, and number of positive nodes were 
used to defme nodal disease. 
Lastly, serum LDH, representing hepatic involvement, was used to 
. IVd' 4s categonze stage 1sease. · 
Accurate melanoma staging requires not just histological analysis but a thorough 
clinical examination as well, with particular focus given to the skin, lymph nodes, 
liver and spleen. Additionally, a complete review of systems should be performed 
to implicate or exclude metastatic disease.4 
Treatment 
Excision is the standard of care for melanoma treatment. In situ melanomas 
should be excised with a margin of non-diseased skin of 0.5 em; melanomas < 
2mm require a 1 em margin; and melanomas equal to or thicker than 2 mm 
require a 2 em border.4 No significant benefit has been demonstrated with deeper 
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or wider excisions although UK guidelines do vary slightly.4 Lymph node 
dissection is reserved for patients who exhibit clinically evident lymph node 
involvement in discreet drainage areas.4 Adjuvant therapy is recommended 
primarily for individuals with stage III cancers and includes melanoma vaccines 
and high dose interferon alfa-2b, which has not been proven to improve disease 
free intervals or overall survival.4 Palliative and "survival prolonging therapy" 
are both still under investigation. 4 
Risk Factors 
Despite recent alarming statistics on the increasing incidence of melanoma in 
younger populations, the median age at diagnosis remains 53 years and incidence 
is extremely rare in children. Although the etiology of melanoma is poorly 
understood, many believe disease development is multifactorial with both primary 
host and environmental risk factors associated with incidence. 6"8 
One of the more broadly researched host factors is family history of 
melanoma, commonly defined as two or more first degree relatives with a history 
of melanoma. Some studies indicate that those with a family history of melanoma 
are more likely to present at a younger age with thinner melanomas and greater 
likelihood of multiple primary melanomas. 8 Beyond representing a hereditary 
marker of disease, this trend may correlate with increased awareness and 
screening on the part of those who have social familiarity with melanoma. Still, 
some susceptibility genes have been-identified in groups of high-risk families 
which leml>sU:Wbrt to a hereditary disease pathway as well as genetic etiology. 8 
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Skin type is another risk factor that has been investigated frequently and 
reliably associated with melanoma development. Reports consistently indicate 
that fair-skinned persons and those with a propensity for freckling are more likely 
to develop melanoma than those with a darker complexion.7• 8 However, this 
assessment has persistent measurement difficulties with recent studies suggesting 
that an individual's ability to tan, rather than the color of unexposed skin, serves 
as a better risk factor for melanoma. 8 There is also strong epidemiologic evidence 
supporting the number of nevi as a melanoma risk marker.8 However, 
distinguishing between nevi types and the potential effects of each has been 
difficult. 8 
Most research indicates that sun and ultraviolet radiation exposure are the 
environmental risks that have the greatest influence on melanoma incidence. 7• 8 
However, the studies are plagued by the difficulty of assessing the validity of 
retrospective recall of sun exposure by study participants. Sunburn incidence 
proves problematic not just because of recall bias, but also because it is a result of 
both host susceptibility and sun exposure patterns (i.e. recreational, 
occupational). 8 In addition, analysis of the significance oflifestyle habits that 
may affect ultraviolet radiation exposure, such as tanning bed use, have yielded 
mixed results with some studies citing no association with melanoma incidence. 7 
Still, collective data indicate that ultraviolet exposure is important in all stages of 
melanoma development.8 
Despite the difficulty in measuring melanoma risk factors, most researchers 
agree that the epidemiologic evidence is sufficient to establish the most important 
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markers and exposures for melanoma development. 8 And on this etiologic 
framework, most current prevention recommendations and intervention protocols 
are based. The American Academy of Dermatology describes melanoma as a 
completely curable disease when detected early but potentially fatal if allowed to 
progress and metastasize to extra-dermal anatomic sites. This distinction, coupled 
with rising incidence, highlights the medical community's resolution to develop 
appropriate and effective prevention strategies on a primary, secondary, and 
tertiary level. 
An Introtiuction to Prevention 
Prevention is the act of stopping an incident from occurring. In public health 
and medicine, prevention is categorized into three levels: primary, secondary, and 
tertiary. Primary prevention prevents disease from occurring by eliminating its 
causes.9 Secondary prevention detects asymptomatic disease at a point when 
treatment precludes progression. And lastly, tertiary prevention comprises 
initiatives that prevent further progression or minimize morbidity after disease 
presentation.9 Screening is a secondary prevention protocol that detects 
asymptomatic disease while many early detection interventions are more closely 
aligned to tertiary prevention principles. Screening may be used as a step in the 
diagnostic process but, in itself, usually does not confer disease presence.9 The 
debate on whether or not to screen individuals for disease is controversial as 
definitive guidelines for when screening should be employed have not been 
determined; however, most scholars agree that the following considerations be 
made when determining whether or not a screening test be used. 9• 10 
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Estimated prevalence should be high in the population being screened to 
ensure adequate positive predictive value of the test and that the screening 
is cost-effective. In addition, prevalence should be high enough and I or 
disease severity significant enough to produce a considerable burden of 
suffering on society. 
The quality of screening test must be satisfactory with either high 
specificity, high sensitivity, or optimally, both. 
Effective treatment for the disease detected by screening must exist. 
Screening is not to be used in isolation and instead requires follow up by 
the physician for all abnormal results and subsequent treatments. In 
addition, treatment of early disease must be superior to treatment of 
disease at a later state during the usual disease course 
For widespread implementation, cost must be considered with the 
screening test proven to be cost-effective. 
The ideal screening test is inexpensive, administered easily, has minimal 
associated risk or discomfort for the patient, and produces valid, reliable, and 
reproducible results.9• 10 
Melanoma Screening 
The American Cancer Society recommends all adults receive a baseline skin 
examination from a physician with subsequent clinical examinations performed at 
the physician's discretion depending on an individual's risk of disease.n The 
American Medical Association, likewise, recommends physician consult on 
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individual frequency of clinical skin examinations but concludes that skin self-
examinations should be performed on a monthly basis. Supporters argue that (1) 
examination requires only a couple of minutes when performed by a qualified 
observer, (2) is safe, (3) is acceptable to the public, (4) is reliable and (5) 
identifies disease in areas poorly viewed by the examinee.11 However, the 
literature varies in its support of examination 
First, who is classified as a qualified observer is not clear and often does not 
correlate to who treats the majority of American patients. Forty-percent of annual 
office visits are made to a family practitioner or internist. Yet studies indicate 
that dermatologists are not only more likely to detect melanoma but also have 
shorter diagnostic delays than general practitioners. 12 If screening is most 
advantageous when performed by a "qualified observer", research will have to 
determine what the measure of quality will be. Chen et a! compared 
dermatologists' and primary care physicians' accuracy in detecting melanoma and 
concluded that data were insufficient to support either a gatekeeper system of 
PCPs or direct access to dermatologists. 13 As expected, dermatologists generally 
had greater sensitivity than PCPs, but both groups had sensitivity ofless than 50% 
. 13 
m some reports. 
The physical safety of skin examinations is clear since assessment is non-
invasive; however, physical safety does not directly correlate with benign 
practice. Screening may not only increase anxiety among the worried well, but 
also may lower specificity and increase false positive results in order to not miss 
melanoma cases; 14 Most screened lesions referred for biopsy are categorized 
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later as false positive.15 Also, there is some debate on screening's benefit since 
biopsy often is unable to distinguish between benign melanocytic nevi and early 
melanoma in addition to reported difficulties in assessing atypical/dysplastic 
nevi. 14 Misdiagnosis of melanoma is another potential harm associated with 
screening and biopsy; also a diagnosis of thin melanoma, even with optimal 
prognosis, may contribute to discrimination when applying for insurance or to 
unnecessary utilization of the healthcare system for additional biopsies and other 
expensive procedures. 15 
Meta-analyses do indicate that the percentage of thin melanomas diagnosed is 
higher in populations that undergo screening than in those provided standard 
care.15 However, the clinical relevance of this increased detection is uncertain 
since many of these would not evolve to invasive disease and contribute to overall 
melanoma mortality. Further, no randomized trials or case-control studies have 
evaluated skin cancer screening and its effects on mortality rates. 15 Improvements 
in 5-year melanoma survival rates with decreased tumor thickness are often used 
as support for screening programs to identify thinner lesions. 11 However, the 
increase in 5-year survival minimally correlates with changes in cancer 
mortality.16 This may be a result of improved treatment prolonging the life 
expectancy of the same number of cancer patients, effective treatment increasing 
survival period (with resultant decrease in mortality rate) or lead time bias.1 
Ultimately, data indicate that physicians are unable to infer the "effectiveness of 
early diagnosis or treatment from temporal changes in 5-year survival" and that 
this measure does not represent decreased disease prevalence and therefore can 
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not be used as proof of improved interventions in prevention or therapy. 16 Both 
the Institute of Medicine and the United States Preventive Services Task Force 
recommend that clinicians and patients "remain alert" to skin marks suggestive of 
malignancy (i.e. lesions with ill-defined borders, color variation, and increase in 
diameter).ll, 17 Yet neither has found sufficient evidence to support routine 
screening by primary care providers or self-examination by patients. 
Alternative Prevention APProaches 
Heightened awareness of disease signs and symptoms has been shown to be 
effective in other cancer models, specifically breast cancer. Breast awareness is a 
public health model that encourages women to "think in terms of 'what is normal 
for them', highlighting the importance of passive acknowledgment of bodily 
changes as opposed to active seeking of disease signs or symptoms.18 This 
preventive method also imparts a degree of empowerment to women in fighting 
breast cancer which may have benefits that extend beyond specific morbidity and 
mortality related to breast malignancy.19 
Both breast cancer and melanoma are assumed to have a period during disease 
progression in which intervention can have a positive effect on mortality and 
morbidity, making both prime targets for educational campaigns that encourage 
body awareness and assertive health seeking behavior when changes are noted. 
The increased knowledge of the general public regarding breast cancer has 
contributed to heightened vigilance for lumps and, undoubtedly, anxiety and 
overestimation of one's risk. However, increased pre-disease awareness has done 
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much to improve mortality rates. Additionally, increased awareness has not 
eliminated the need for other screening modalities such as mammography nor has 
it impeded the development of new preventive methods. Instead, it has expanded 
the preventive resources offered to populations at risk for breast cancer. 
Likewise, a similar expansion of prevention modalities may prove effective in 
melanoma. 
Methods 
Literature Search 
We began by searching MEDLINE to identify articles relevant to the 
melanoma diagnostic course and, specifically, those discussing patient related 
factors that affect accessing the healthcare system. We used Medical Subject 
Headings (MeSH) as search terms when available or when key words were 
appropriate. We combined terms for our health outcome of choice (broadly 
defined as "melanoma"), "incidence" "mortality", "survival rates", "patient 
awareness", "health knowledge", "patient beliefs", "educational campaigns", 
"disease awareness", "interference in lifestyle I daily activities", "health seeking 
behavior" and "access to care". We limited our electronic searches to "human" 
and "English language" and employed "a snowball technique", using the 
resources found to identify additional relevant sources. Because the available 
research was limited in our topic of interest, we did not restrict our search to 
specific article types and included editorials, case-series, cross-sectional studies, 
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randomized control trials, and meta-analyses in our assessment. In addition, we 
included studies and reports of foreign populations to expand available data. 
Conceptual Framework 
We began our investigation with a comprehensive framework (shown in 
Figure 1) detailing fundamental, intermediate, and proximate factors correlated to 
our outcome of interest: presence of melanoma. 
Figure I: Conceptual Framework 
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Fundamental contributors are broad- based macro level factors that serve 
as the foundation for all other contributors in the development of a 
particular health outcome. We divided our fundamental factors into the 
four broad categories noted above. 
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The intermediate division is defined as intermediary because these factors 
serve as a link between a specific aspect of the etiologic base and factors 
that influence a system's action within the diagnostic process. 
Proximate contributions are those factors that are most closely related to 
the occurrence of a particular health outcome. 
Completing our framework, we determined the factors we considered to 
be the most pertinent aspects of disease outcome: (I) diagnosis of 
melanoma, (2) time between period of initial concern regarding mark and 
melanoma diagnosis (which we further sub-categorized as medical delay 
and diagnostic delay), (3) melanoma characteristics (Breslow depth and 
Clark length), and ( 4) mortality rates. 
The framework employed was adapted from a conceptual outline used to describe 
the correlation between social determinants of health and environmental health 
promotion.20 
Much of the initial research we found focused on the debate between the 
appropriateness of screening and whether there was a need for alternative 
prevention methods. Though somewhat limited, much of the alternative 
prevention literature focused on disease awareness and knowledge and its effect 
on various aspects of melanoma outcome. We felt that determining the 
correlation of pre-disease awareness not to the distal outcome of melanoma 
presence but to the intermediate outcome of patient delay in seeking medical 
attention would contribute to a better, and more concise, understanding of the 
diagnostic process. 
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For this reason, we decided to limit our focus to patient -associated 
fundamental factors and established a list of intermediate factors from which we 
chose prior awareness of disease as our variable of interest. Subsequently, we 
further narrowed our assessment of proximate factors to those individual and 
population-level factors that could influence a patient's ability to access the 
healthcare system. Relevant concepts are listed in our framework at each factor 
level but this list is by no means comprehensive. We limited inclusion of 
potential contributors to those with the greatest likelihood of available literature 
and to those in which we had the greatest interest. Lastly, in our framework, we 
broadened our distal outcome category beyond disease presence because we 
wanted to assess the outcome process which, similar to its contributing factors, is 
multi-faceted. Still, our primary outcome of interest is patient-associated medical 
delay which we define as the period between the point when the patient becomes 
concerned about his I her skin mark and his I her visiting a physician for 
evaluation of the lesion. 
Instrument Development 
We concluded a survey would be an adequate method of assessing both 
patient prior awareness of disease and delay in seeking medical attention 
following concern of the suspicious lesion (shown in Appendix). We reviewed 
the medical literature for dermatologic questionnaires pertinent to melanoma to 
develop the questions that would be used in our survey. Few published models 
were found, but we did locate the Public Health Survey developed at Yale 
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University from which we adapted many of our questions. We also reviewed 
articles to see how questions were phrased in interviews and telephone surveys for 
better validation of the question format we used. Additionally, we searched for 
health literacy assessment tools. The REALM was felt to be a good assessment 
tool with an estimated completion time of7 minutes, but we wanted to use a 
device that did not require the assistance of an interviewer as this staff was not 
included in our original research plan. The Short Test of Functional Health 
Literacy in Adults (S-TOHFLA) proved similarly problematic as an interviewer 
was required. Chew et a! adapted a 3-question tool to assess health literacy which 
yielded adequate sensitivity in their analysis, but demonstrated poor efficacy in 
identifying those with moderate to minimal health illiteracy_ll Another potential 
limitation to our use of this assessment tool is that it only has been evaluated in 
this study and its results not confirmed by outside parties. 
Instrument Validation 
We intentionally modeled our questions from those used in previous works to 
increase the validity of our survey. Still, we believe further validation of the 
survey via a trial administration will be required to ensure that our patient 
population is able to understand and complete the questionnaire with minimal 
difficulty. A trial administration also will allow us to estimate the required 
completion time more accurately. We propose a trial administration, employing 
15 - 20 patients who will be asked to complete the questionnaire in the presence 
of research staff. The researcher will be able to address any questions the patient 
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has at that time, and difficulties will be noted for survey modification. The survey 
will be changed based on which questions elicit the most concern from pilot 
respondents. 
Sample size calculation 
a=O.OS 
Power= 0.80 
~=0.20 
n = sample size 
n = [ (z a + z ~ )s I I'>] 2 = [ (1.96 + 1.28) x 169 I 90] 2 = 37.01 = 38 patients 
Discussion 
Even with an extensive history of signs and symptoms, many melanoma 
patients still delay evaluation of suspicious skin lesions. 22 There are a number of 
reasons for this delay, and lack of awareness of melanoma by both the general 
public and physicians within the United States is a very likely contributor. Self-
detection of suspicious lesions is the most commonly reported mode of melanoma 
detection, 22 which implies patient knowledge of suggestive disease signs is of 
considerable importance. Therefore, promoting disease awareness and patient 
pro-activity may prove to be an effective method of tertiary prevention, 
significantly impacting mortality rates of invasive melanoma. 
Prospective studies of current prevention methods, both screening and patient 
awareness I early detection initiatives are needed to provide more definitive proof 
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of their benefit. One such study of screening protocols was being conducted in 
Queensland, Australia, the country with the greatest incidence of melanoma in the 
world.23 The prospective randomized trial was to investigate the effectiveness of 
a multi-component community-based early detection intervention that included 
thorough skin self-examinations (TSSEs), whole body examination by primary 
care physicians, and specialized screening clinics. 23 The completed results were 
to be published in 2015,23, but investigators encountered funding difficulties 
which required changes to the study design. This, in turn, decreased the sample 
size and, subsequently, the generalizability of reported results.24 Still, preliminary 
unpublished data indicate 16,3 83 full body skin examinations were performed, 
resulting in 2,302 referrals for suspicious lesions of which 222 were thought to be 
melanoma.25 Of those lesions biopsied, thirty-three were diagnosed as melanoma 
with an overall specificity of 86.1% for detecting melanoma and positive 
predictive value of2.5 percent.25 It was also reported that those with thinner 
melanomas were more likely to have a clinical skin examination within the past 3 
years when compared to those with thicker melanomas. 
These data substantiate past case series reports of similar results with the 
additional benefit of greater reliability and generalizability secondary to the 
study's larger sample size. Yet, how detection of these thin melanomas affects 
mortality rates still is to be determined. Two studies, both of significant sample 
size, conducted in a country with high melanoma incidence (Australia) and over a 
long period (30-year longitudinal follow-up at Duke University) determined that 
those with thin melanomas had low rates of recurrence and longer periods of 
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nodal stams, primary tumor ulceration, and disease recurrence are all associated 
with greater mortality,28• 29yet tumor thickness (> 6mm) carries a 5-year survival 
rate above 50%, suggesting this characteristic alone does not always lead to poor 
outcome.28 Furthermore, whether tumor thickness is (a) the result of aggressive 
growth over a short period of time or (b) the result of longer period of 
development (i.e. delayed diagnosis) has not been determined. This distinction is 
important in establishing prevention guidelines as the former is the type more 
amenable to intervention. 
In order to support any intervention method, we must assume that melanoma 
is a curable disease if found early for all types30, or at the very least, the more 
malignant forms. These considerations demonstrate the importance of 
determining melanoma's etiologic framework prior to developing and evaluating 
possible prevention interventions. For example, the biologic process of 
melanoma must be delineated more clearly. One of the primary guidelines in the 
establishment of prevention protocols is that early detection decrease the 
morbidity and mortality associated with disease.9• 10 This intervention must not 
just increase lead time bias with a false lengthening of survival (an argument that 
arises from the use of 5-year survival rates as an outcome measure) but intervene 
in a stage of disease that causes a change in mortality rate. There have been 
tremendous advances in the genetic smdy of melanoma, contributing to a better 
understanding of the biologic and molecular components of melanoma. 8 Still, 
few melanoma have been attributed to particular germline mutations in identified 
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genes, and thus more studies are required to assess the interaction between 
host/environmental factors and genetic susceptibility. 8 
Additionally, melanoma should be qualified by histological type in SEER data 
so that we may better assess those types that carry the greatest mortality risk. 
Specific classifications can be further evaluated by determining medical delay, 
patient-related correlations, and other diagnostic features associated with each. A 
better schematic of the etiologic framework and the accompanying malignant 
interval associated with disease development (defined as the time period required 
for the development of a malignant lesion) will allow for development of 
interventions that better target those exposures that can be modified in a time 
period to reduce both morbidity and mortality. We may also better determine 
which patient populations carry a greater mortality risk so that specific prevention 
modules be specifically targeted to them. 
Furthermore, if protocols are developed to determine the efficacy of education 
campaigns, investigators still must define those factors that are most important 
and of which participants should be aware. As discussed previously, there is a 
general consensus of what factors are most commonly associated with melanoma 
incidence, but these conclusions are based on qualitative data with definitions of 
exposures that vary by study group and results that are hampered by dependency 
on patient recall. Optimally, those factors that consistently have been correlated 
to melanoma incidence should be defined in a specific manner employed by all 
researchers. In turn, patients with these factors should be followed prospectively 
and compared to the general population to determine better the odds ratios 
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associated with each possible exposure. This type of study would allow for the 
establishment of particular exposure guidelines and lesion characteristics from 
which the education module can be developed. By doing so, we would be able to 
refine what constitutes high risk groups and ultimately develop better prevention 
recommendations whether they be on a primary (avoidance of disease), 
secondary or tertiary (detection of early disease) level.8 
After establishing risk factors, signs I symptoms, and points of intervention, 
we next consider how best to implement an effective program based on these data. 
Currently, no method has been researched with sufficient results to earn universal 
support of its implementation. Again, we propose a step-wise analysis of the 
diagnostic process of melanoma, and ideally, intervention research would follow 
these etiologic investigations. However, we will discuss proposed intervention 
methods at this time for completeness' sake. 
The first step in establishing prevention protocol is determining who will be 
responsible for implementing the. proposed activities: the patient, the general 
practitioner, the dermatologist, etc. Specialists in skin would appear to be the best 
choice for a first-line defense against melanoma. However, utilizing 
dermatologists in a global prevention plan presents some difficulties. Previous 
reports indicate that dermatologists' care varies from practice to practice with 
some dermatologists not performing annual full-body skin examinations on all 
patients or even on all new patients. 24 One suggested intervention would require 
that a standard be set for all practicing dermatologists24, perhaps requiring initial 
skin examinations of all patients and more frequent exams for those with greater 
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perceived risk. Still, one must consider that access to dermatologists often is 
limited and not offered to a broad segment of the population. According to the 
National Ambulatory Medical Care Survey: 2002 Summary, dermatology care 
accounted for less than 4% of annual medical office visits.31 Primary care 
physicians, on the other hand, interact with larger numbers of the American public 
and may serve as an appropriate group to whom public health initiatives can be 
targeted.24 In 2002, fifty-five percent of all office visits were to general/family 
practice, internal medicine, or pediatric practices. 31 Yet, passing the baton of 
patient education and annual examinations to primary care physicians still may 
prove problematic. 
During office visits, primary care clinicians often must address acute care 
issues as well as a number ofUSPTF-supported activities. These primary duties 
coupled to limited blocks of time may serve as a barrier for this group providing 
skin cancer prevention.24• 32 When evaluating the diagnostic process of 
melanoma patients, some reports reveal longer diagnostic delays in melanoma 
patients evaluated by primary care physicians as well as greater tumor depth. 12 
The reason for this inequality probably is multi-fold, including (1) lower 
incidence of melanoma in general practice (compared to dermatology clinics), (2) 
subsequent difficulty in retaining melanoma pattern recognition, and (3) 
inadequate training of general practitioners.12 Most primary care clinicians 
believe they receive limited training in melanoma detection, which correlates to a 
higher degree of insecurity in their skin examination skills and subsequently leads 
to a decreased likelihood of reviewing any portion of the skin during the clinic 
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visit.24• 33 Despite these factors, some studies indicate that primary care 
physicians are actively participating in skin cancer prevention. One survey 
reported 60% ofPCPs performed routine skin examinations with their high risk 
patients34, and a second of family practice and internal medicine doctors reported 
similar incidence of clinical skin examinations with use being strongly correlated 
to the perceived importance of screening by physicians. 35 One Connecticut 
survey of general practitioners differed in the reported incidence of clinic skin 
exams with less than half of the respondents indicating they "often perform" 
clinical full skin examinations; however, of those that noted suspicious lesions, 
most made a referral to a dermatologist.33 
Ultimately, because of broader access to the general public and ability to refer 
to dermatologists when appropriate, primary care physicians still may be the best 
option in screening which patients warrant greater attention. Limiting skin 
surveillance programs to a targeted population that is at greatest risk for 
melanoma development is a proposed modification to the current skin 
examination recommendations. Targeted screening within high-risk populations 
could maximize the number of melanoma lesions detected which is of greatest 
importance in those countries where malignant melanoma incidence is low, like 
the United States.36 Targeted screening programs by primary care clinicians has 
been suggested previously, but some researchers countered that this method 
would increase physician workload (which is already stretched thin in many 
clinical practices) and negatively affect the public economically as well as 
psychologically by increasing unnecessary testing, procedures, and patient 
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anxiety.37 Additionally, to have a significant impact on mortality and implement 
ethical public health interventions, we still must determine who is at greatest risk 
of poor melanoma outcome. 
On the other hand, patients are employed in almost all facets of prevention 
protocols. In primary prevention efforts such as reduction of sun I UV exposure, 
patients are asked to change behavior in order to decrease risk. Many believe that 
this method alone will not adequately address melanoma mortality as these 
measures have not produced a decrease in melanoma incidence/0 and even when 
effective may require 20+ years of follow-up before changes in incidence or 
mortality are recognized. 38 This delay in benefit is primarily the result of this 
method's requirement of behavior modification by the targeted population. While 
sun-awareness campaigns do increase public knowledge of the potential risk of 
skin cancer development, they do not produce individual behavioral changes?9 
In secondary prevention, patients (and physicians) are encouraged to look for 
suspicious marks in order to detect cancerous lesions early. In a survey of I ,000 
participants from a 43-state sample, approximately 46% said they closely 
examined themselves for signs of skin cancer or melanoma, most commonly, 
looking for things that weren't there before (34.2%) and changes in moles 
(21. 7% ). 40 Of those who practice self skin examinations, a smaller number have a 
delay in diagnosis when compared to their counterparts who do not, with shorter 
diagnostic delays correlating to thinner melanomas in one Connecticut case 
control study of 650 melanoma patients.41 As mentioned previously, these thinner 
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melanomas are associated with better individual outcomes, but global 
implications on mortality and morbidity are uncertain. 
For many, the greatest debate exists between whether to employ a "look and 
see" intervention as recommended by Brown University dermatologist Martin 
Weinstock, M.D., or to use one of"awareness, see and take action". In discussing 
public health approaches to early detection, Weinstock proposes an intervention 
that encourages the public to inspect the skin for possible melanoma lesions 
(look) and identifY those lesions at an early, curable stage (see).24 For such an 
intervention program to be successful, however, the public and healthcare 
professionals must be encouraged to perform skin examinations and be educated 
to know for what they are looking. In 2000, British researchers determined that 
general public skin examination campaigns would not be cost-effective because of 
the low incidence of disease among the population. 37 With an estimated 
incidence in the United States of 62,190 cases in 2006 2, a similar conclusion may 
be drawn. Of those who would benefit from this type of intervention, Weinstock 
notes that monthly TSSEs are "associated with a substantial reduction of 
melanoma mortality risk"24; yet these data are not substantiated by many other 
published reports of melanoma mortality rates. 
Despite the low predictive measures of almost all of the currently 
recommended prevention protocol, we still believe interventions are needed to 
decrease melanoma incidence. The American Academy of Dermatology has 
sponsored annual skin cancer programs since 1985, and the effort was evaluated 
approximately 10 years later to determine its impact on melanoma diagnosis.42 
Addendum 25 
Researchers contacted 96% of all persons (4,458) with suspected melanoma at 
screening and acquired the fmal pathologic diagnosis of 72 percent. 42 Three-
hundred and sixty-four participants were diagnosed with melanoma with a 
positive predictive value of 17%.42 The majority of those lesions found were thin 
with a median thickness of 0.33mm with advanced disease only representing 
8.3% of the total.42 Perhaps, this diagnostic discrepancy indicates that the 
program is operating appropriately with disease being identified in an early stage 
when a favorable prognosis is more likely. Conversely, the lack of advanced 
disease may indicate the program's inability in recruiting those at greatest risk for 
having lesions with the greatest malignant potential. Measuring which is true is 
difficult and requires more extensive analysis of who is and is not being screened. 
Ultimately, the true efficacy of the AADA's project still is unknown. Those 
who were not believed to have "suspicious lesions" were not biopsied to ensure 
no melanoma existed, making calculation of specificity and negative predictive 
value impossible. In addition, participants were not followed prospectively to see 
if they modified risky behavior, maintained annual skin examinations, or 
eventually developed melanoma. Nonetheless, despite a low proportion of 
diagnosed cases and potential limitations to the evaluation of the program, the 
American Academy of Dermatology as well as physicians participating in the 
screening still believe the project is beneficial. The project is not just an 
opportunity for clinical full-body skin examination but, more importantly, is a 
platform from which information about melanoma, sun protection, and early 
detection can be distributed. 42 
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We believe continued educational campaigns will prove beneficial in the 
future. The public should be made aware of what melanoma is, educated to what 
the most common presenting signs and symptoms are, and encouraged to seek 
medical attention if suspicious lesions of similar appearance arise. Education 
campaigns, targeted to the general public, should re-identify the ABCDs of 
melanoma (asymmetry, irregular border, color variegation, diameter> 6mm) with 
additional emphasis on the importance of recognizing new lesions or changes to 
existing moles I marks; both of which are cited as a strong, if not the strongest, 
pre-diagnostic predictor of melanoma in recent publications.24• 32 
This information can be conveyed in public service announcements in various 
media outlets (television, radio, newspaper ads) as well as waiting room 
pamphlets available in all medical facilities. Education campaigns also should 
target physicians and other health professionals via brochures, luncheons, and 
seminars during medical conferences for which participants can earn Continuing 
Medical Education credit. These projects should be analyzed to determine both 
costs and effectiveness. We would employ a prospective cohort study design with 
a random nationwide sample of (1) individuals exposed to our education 
campaigns and (2) those individuals who are not likely to be aware of our 
intervention. Differences between the populations would be noted with the 
following characteristics evaluated: presence of disease awareness, melanoma-
risk behavior, incidence of melanoma and relevant characteristics (type, depth, 
diagnostic delay), and mortality rates. As a sub-analysis, we would survey the 
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exposed group at various follow-up points to determine if there were any changes 
in awareness and/or behavior. 
Because we are not looking, will we not detect melanoma?24 We do not think 
this is the case as other preventive methods exist outside of screening that may 
prove to be just as beneficial and cost-effective. Patient education has increased 
the public's seeking medical attention for a variety of diseases. 18• 43• 44 Therefore, 
a similar focus on patient knowledge of melanoma and awareness of relevant 
dermatologic changes should prove similarly helpful in addressing melanoma 
incidence. While we specifically do not encourage "looking for" melanoma, we 
do support global awareness so that suspicious lesions are noted, patients seek 
care more quickly, and the medical community be able to evaluate and diagnose 
melanoma earlier. 
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Appendix I 
Questions l- 6: Disease Knowledge 
We would like to learn how much you knew about melanoma one vear prior to vour 
recent skin biopsy. 
1. Before your recent skin biopsy. did you know what melanoma was? 
o Yes 
o No 
2. Before your recent skin biopsy, what characteristics did you believe were 
related to melanoma? Please check all that you believed were true. 
o Dark I varied color 
o Large size 
o Abnormal shape 
o Change in shape, color or size of a mark or mole 
o Hair growing in mole 
o Bleeding 
o Elevation of mark 
o Itching 
o Multiple development of new moles 
o Scab that doesn't heal 
o Other (please specify):.,..---..,.--,---,----,---,---
o I did not know of any characteristics related to melanoma. 
3. Before your recent skin biopsy, were you able to identify any risk factors for 
melanoma? 
o Yes- If you answer yes, go to Question 4. 
o No -If you answer no, go to Question 5. 
4. Before your skin biopsy, what risk factors did you believe were associated 
with melanoma? Please check all factors that you believe apply. 
o Light I fair skin color 
o Moles 
o History of recreational sun exposure 
o Freckles 
o Red hair and blue eyes 
o Brown hair and brown eyes 
o Personal history of melanoma 
o Personal history of diabetes 
o Presence of moles and freckles 
o Tanning beds 
o History of severe sunburn occurring early in life 
o Family history of melanoma 
5. Before your recent skin biopsy, did you know what a melanoma looked like? 
o Yes 
o No 
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6. At the time you first became concerned about the mark on your skin, what 
made you think it might be melanoma?" Please check all that apply. 
o Dark I varied color 
o Large size 
o Abnormal shape 
o Change in shape, color or size of a mark or mole 
o Hair growing in mole 
o Bleeding 
o Elevation of mark 
o Itching 
o Multiple developments of new moles 
o Scab that doesn't heal 
o Other (please specify); __________ _ 
o None of the above. 
Questions 7- 9:.Skin Awareness 
W'e are trying to evaluate how much you thought about your skin, onevear prior to 
vour recent skin biopsv. 
7. Before your recent skin biopsy, about which of the following aspects of your 
skin did you think? Please check all that apply. 
o Cosmetic changes in my skin (e.g., wrinkles, hair loss) 
o Other changes in my skin like change in moles, appearance of new moles. 
o Abnormal marks that were already on my skin. 
o Other (please specify) 
o I did not think about my skin before the biopsy. 
8. Before your recent skin biopsy, did you check your skin? 
o Yes If you answer yes, please go to question 10. 
o No If you answer no, please go to question 11. 
9. When you checked your skin, what did you do? 
o I looked at a particular mark. 
o I casually checked my skin 
o I did a deliberate skin examination. 
o None of these. 
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Questions 10 -13: Mark Appearance I Mole Ilistory · · 
We would/ike for you tote/Ius more about your noticing the mark or mole that was 
biopsied. . . 
For questions IO and II, please give us the following dates (month /year): 
I 0. First time you noticed the mark. 
11. First time you became concerned about it. 
12. Did another person tell you about the mark I mole before you noticed it? 
o Yes 
o No 
13. If you answered yes to Question 12, please indicate who also noticed the 
mark. 
o Myspouse 
o Other family member 
o Friend, acquaintance 
o Physician 
o Other (please specifY): 
Questions 14 ~.20: Accessing the llealthcare System 
We would/ike you to tell us more about what happened after you became concerned 
about yourskill mark. 
·. .. . . . . 
14. After becoming concerned about the mark, did you see a healthcare 
professional (doctor, nurse practitioner, physician assistant) about the mark? 
o Yes 
o No 
15. Who was the first health professional you saw about the mark? (Please give 
us his/her name) 
16. What type of health professional is the doctor named in Question 15? 
o Family Practice physician 
o Internist 
o Obstetrician- Gynecologist 
o Dermatologist 
o Surgeon 
o Other (please specifY): 
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17. Where is this health professional located? (Please give us the city and state of 
the medical office where you went) 
18. When did this healthcare professional first look at the mark? (Month I Year) 
19. Did more than 6 months pass from the time you noticed the mark to the time 
you saw a physician? 
o Yes 
o No 
20. If more than 6 months passed between your noticing the mark and you seeing 
a physician, please tell us why. 
QU."'stions 21: Socialfamiliarity 
We would like to know if others in your family have had. melanoma. 
21. Has someone close to you had melanoma? 
o Yes 
o No 
-:-. Questions 22 -'" 25: Usual Pattern of Health care 
We would like to know how often you saw a doctor before having your recent skin 
biopsy. 
.· 
22. Do you at least have one doctor whom you see at least once a year? 
o Yes 
o No 
23. Before your recent skin biopsy, how often did you have a general medical 
check-up even though you did not feel ill or perceive any serious illness? 
Please list number of visits per year: 
. 
.. 
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24. In the two years before your biopsy, how often did you visit your doctor? 
o More often than usual-If you answer "more", please answer question 25. 
o Less often than usual-If you answer "less", please answer question 25. 
o Same as usual 
25. If the number of times you visited the doctor was more or less than usual, 
why do you believe it changed? 
Questions 26 -30: Usual patt~rn of dermatologic care · · ·. 
WewouJd like to get an idea about how often you sought care specificallyforyour 
skin at/east one year prior to your recent biopsy . 
. ·· .• . 
26. Has there been a change in the frequency of skin exams (by you or a doctor)? 
o Yes 
o No 
27. If yes, how have they changed? 
o Increase 
o Decrease 
28. If yes, at what age, did the change of skin exam frequency occur? 
29. Why do you believe these changes occurred? 
30. Had any doctor examined your skin within 3 years before your diagnosis? 
o Yes 
o No 
Appendix6 
QnestiC)Iis 31-33: IIealth Literacy 
We want to askyou a couple ofquestions about howfamiliar you are with the 
healthcare system. 
31. How often do you have someone help you read hospital materials? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
32. How confident are you filling out medical forms by yourself? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
33. How often do you have problems learning about your medical condition 
because of difficulty understanding written information? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
Questions 34 - 40: General Demographics . 
This is the final section of the questionnaire. We would like to ask you some 
· questions aboutgeneralinformation like insurance, income, education level, and 
race. . . . . . 
34. Sex: 
o Female 
o Male 
35. Race: 
o White 
o Black 
o Hispanic I Latino 
o Asian I Pacific Islander 
o Other: --------------
36. What is your age (in years)? _____ _ 
37. Marital Status: 
o Married 
o Single 
o Widowed 
o Divorced 
38. Household Income: 
o Less than $25,000 
D $25,000- $49,999 
D $50,000- $74,999 
o More than $75,000 
39. Did you graduate from high school? 
o Yes 
o No 
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40. During the past 5 yeas, have you had medical insurance that covers office 
visits? 
o Yes 
o No 
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Questions 1 - 6: Disease. Knowledge 
We would like to/earn how muc:h you knew about melanoma one rear prior to Your 
recent skin biopsy; 
1. Before your recent skin biopsy, did you know what melanoma was? 
o Yes 
o No 
2. Before your recent skin biopsy. what characteristics did you believe were 
related to melanoma? Please check all that you believed were true. 
o Dark I varied color 
o Large size 
o Abnormal shape 
o Change in shape, color or size of a mark or mole 
o Hair growing in mole 
o Bleeding 
o Elevation of mark 
o Itching 
o Multiple development of new moles 
o Scab that doesn't heal 
o Other (please specify)::-----:---:---:---:-------::--~ 
o I did not know of any characteristics related to melanoma. 
3. Before your recent skin biopsy, were you able to identify any risk factors for 
melanoma? 
o Yes -If you answer yes, go to Question 4. 
o No- If you answer no, go to Question 5. 
4. Before your skin biopsy, what risk factors did you believe were associated 
with melanoma? Please check all factors that you believe apply. 
o Light I fair skin color 
o Moles 
o History of recreational sun exposure 
o Freckles 
o Red hair and blue eyes 
o Brown hair and brown eyes 
o Personal history of melanoma 
o Personal history of diabetes 
o Presence of moles and freckles 
o Tanning beds 
o History of severe sunburn occurring early in life 
o Family history of melanoma 
5. Before your recent skin biopsy, did you know what a melanoma looked like? 
o Yes 
o No 
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6. At the time you first became concerned about the mark on your skin, what 
made you think it might be melanoma?" Please check all that apply. 
o Dark I varied color 
o Large size 
o Abnormal shape 
o Change in shape, color or size of a mark or mole 
o Hair growing in mole 
o Bleeding 
o Elevation of mark 
o Itching 
o Multiple developments of new moles 
o Scab that doesn't heal 
o Other (please specify): __________ _ 
o None of the above. 
Questions 7-'- 9:SkinAwareness 
J¥e are tryingto evaluate how much you thought about your skin, one year prior to 
yourrecent skin biopsy. 
7. Before your recent skin biopsy, about which of the following aspects of your 
skin did you think? Please check all that apply. 
o Cosmetic changes in my skin (e.g., wrinkles, hair loss) 
o Other changes in my skin like change in moles, appearance of new moles. 
o Abnormal marks that were already on my skin. 
o Other (please specify) 
o I did not think about my skin before the biopsy. 
8. Before your recent skin biopsy, did you check your skin? 
o Yes If you answer yes, please go to question 10. 
o No If you answer no, please go to question 11. 
9. When you checked your skin, what did you do? 
o I looked at a particular mark. 
o I casually checked my skin 
o I did a deliberate skin examination. 
o None of these. 
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. Questions 10 -13: Mark Appe!lrance l Mole History 
We would/ike/or you to tell us more about your noticing the mark or mole that was 
biopsied. . . . . 
For questions 10 and 11, please give us the following dates (month/year): 
10. First time you noticed the mark. 
11. First time you became concerned about it. 
12. Did another person tell you about the mark I mole before you noticed it? 
o Yes 
o No 
13. If you answered yes to Question 12, please indicate who also noticed the 
mark. 
o Myspouse 
o Other family member 
o Friend, acquaintance 
o Physician 
o Other (please specifY):------------------
Questions 14-20: Accessing the Healthcare System 
We would like you to tell us more about what happened after you became concerned 
about your skin mark . 
. · 
14. After becoming concerned about the mark, did you see a healthcare 
professional (doctor, nurse practitioner, physician assistant) about the mark? 
o Yes 
o No 
15. Who was the first health professional you saw about the mark? (Please give 
us his/her name) 
16. What type of health professional is the doctor named in Question 15? 
o Family Practice physician 
o Internist 
o Obstetrician- Gynecologist 
o Dermatologist 
o Surgeon 
o Other (please specify): 
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17. Where is this health professional located? (Please give us the city and state of 
the medical office where you went) 
18. When did this healthcare professional first look at the mark? (Month I Year) 
19. Did more than 6 months pass from the time you noticed the mark to the time 
you saw a physician? 
o Yes 
o No 
20. If more than 6 months passed between your noticing the mark and you seeing 
a physician, please tell us why. 
Questions 21: Socialfamili;uity 
We would like to know if others inyour family have had melanoma. 
21. Has someone close to you had melanoma? 
o Yes 
o No 
1 
. Questions 22 - 25: Usual Pattern of Health care 
We would like to know how often you saw a doctor before having your recent skin 
1 
biopsy. . 
22. Do you at least have one doctor whom you see at least once a year? 
o Yes 
o No 
23. Before your recent skin biopsy, how often did you have a general medical 
check-up even though you did not feel ill or perceive any serious illness? 
Please list number of visits per year: 
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24. In the two years before your biopsy, how often did you visit your doctor? 
o More often than usual- If you answer "more", please answer question 25. 
o Less often than usual- If you answer "less", please answer question 25. 
o Same as usual 
25. If the number of times you visited the doctor was more or less than usual, 
why do you believe it changed? 
·. Qn~stions 26-30: Usnalpatt~rnof d~rmatologic car~ 
We. would like to get an idea about how often you sought care specifically for your ·· 
skin atleastone yearprior to your recentbiopsw 
·. . .. . .· . .• . ·. 
26. Has there been a change in the frequency of skin exams (by you or a doctor)? 
o Yes 
o No 
27. If yes, how have they changed? 
o Increase 
o Decrease 
28. If yes, at what age, did the change of skin exam frequency occur? 
29. Why do you believe these changes occurred? 
30. Had any doctor examined your skin within 3 years before your diagnosis? 
o Yes 
o No 
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Q ....u··.·.es .. « .... ·on.s 31···.:.:.3·3·: Hea.lth .. L.iteracy .. ~e ~ant to ask you a couple of questionsabout how familiar you are With the 
healtf!care system. 
31. How often do you have someone help you read hospital materials? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
32. How confident are you filling out medical forms by yourself? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
33. How often do you have problems learning about your medical condition 
because of difficulty understanding written information? 
o Never 
o Occasionally 
o Sometimes 
o Often 
o Always 
Questions 34- 40: General Demographics 
This is the final secti()n of the questionnaire. Wewould like to ask yousome 
questions about general information like insurance, income, education level,. and 
~. . 
34. Sex: 
o Female 
o Male 
35. Race: 
o White 
o Black 
o Hispanic I Latino 
o Asian I Pacific Islander 
o Other: 
---------------------------
36. What is your age (in years)? __________ _ 
37. Marital Status: 
o Married 
o Single 
o Widowed 
o Divorced 
38. Household Income: 
o Less than $25,000 
0 $25,000 - $49,999 
0 $50,000 - $74,999 
o More than $75,000 
39. Did you graduate from high school? 
o Yes 
o No 
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40. During the past 5 yeas, have you had medical insurance that covers office 
visits? 
o Yes 
o No 
